Similar articles

• Bortezomib plus melphalan and prednisone for multiple myeloma.

  Tsubokura M, Kami M, Komatsu T. Tsubokura M, et al. N Engl J Med. 2008 Dec 11;359(24):2613; author reply 2613-4. N Engl J Med. 2008. PMID: 19090031 No abstract available.
• Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.

  Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Morabito F, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Ciccone G, Boccadoro M. Palumbo A, et al. J Clin Oncol. 2010 Dec 1;28(34):5101-9. doi: 10.1200/JCO.2010.29.8216. Epub 2010 Oct 12. J Clin Oncol. 2010. PMID: 20940200 Clinical Trial.
• Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

  San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG; VISTA Trial Investigators. San Miguel JF, et al. N Engl J Med. 2008 Aug 28;359(9):906-17. doi: 10.1056/NEJMoa0801479. N Engl J Med. 2008. PMID: 18753647 Clinical Trial.
• Advances in therapy of multiple myeloma.

  Bladé J, Rosiñol L. Bladé J, et al. Curr Opin Oncol. 2008 Nov;20(6):697-704. doi: 10.1097/CCO.0b013e3283136984. Curr Opin Oncol. 2008. PMID: 18841053 Review.
• [Multiple myeloma].

  Iida S. Iida S. Rinsho Ketsueki. 2012 Feb;53(2):155-63. Rinsho Ketsueki. 2012. PMID: 22450574 Review. Japanese. No abstract available.